Objective: To investigate the efficacy of
sodium zirconium cyclosilicate on emergency correction of
hyperkalemia in
chronic kidney disease patients. Methods: Patients with
chronic kidney disease who were admitted to the Department of Nephrology of the First Affiliated Hospital of Zhengzhou University from May to June 2020 were selected. Those who had
hyperkalemia and took
sodium zirconium cyclosilicate powder were finally included. The patient's clinical data and laboratory results were collected. Results: A total of 24 results were included from 21 patients. The age of patients was (48.9±13.5) years old. Fourteen patients were male, and 7 patients were female. After 2 hours of administration, the venous
potassium level decreased from (5.85±0.52) mmol/L to (5.15±0.43) mmol/L (P<0.001, n=21), with an average decline of (0.71±0.43) mmol/L. Meanwhile, the arterial
potassium level decreased from (5.50±0.40) mmol/L to (4.88±0.33) mmol/L (P<0.001, n=10), with an average decline of (0.62±0.29) mmol/L. Based on the initial venous
potassium level, the patients were further divided into three groups. The average
potassium decrease in<5.5 mmol/L group (4 patients), 5.5-<6.0 mmol/L group (11 patients) and ≥6.0 mmol/L group (6 patients) was (0.46±0.26) mmol/L, (0.62±0.38) mmol/L and (1.04±0.45) mmol/L, respectively. There was statistically significant difference of
potassium reduction among the three groups (P=0.045). Moreover, the extent of
potassium reduction was positively correlated with baseline venous
potassium level (r=0.603, P=0.004, n=21). The study did not reveal any treatment-related adverse event. Conclusion:
Sodium zirconium cyclosilicate powder can rapidly and effectively reduce the serum
potassium level in
chronic kidney disease patients with
hyperkalemia.